



Universiteit
Leiden
The Netherlands

Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?

Ojha, R.P.; Steyerberg, E.W.

Citation

Ojha, R. P., & Steyerberg, E. W. (2018). Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses? *Journal Of Hepatology*, 69(2), 551-553. doi:10.1016/j.jhep.2018.02.037

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/77509>

Note: To cite this publication please use the final published version (if applicable).

Manuscript Number:

Title: Real-World Data on Antiviral Treatments for Hepatitis C Virus
Infections: Can We Define Intention to Treat or Per Protocol Analyses?

Article Type: Letter to the Editor

Corresponding Author: Dr. Rohit P Ojha, DrPH

Corresponding Author's Institution: JPS Health Network

First Author: Rohit P Ojha, DrPH

Order of Authors: Rohit P Ojha, DrPH; Ewout W Steyerberg

LETTER TO THE EDITOR

Real-World Data on Antiviral Treatments for Hepatitis C Virus Infections: Can We Define Intention to Treat or Per Protocol Analyses?

Rohit P. Ojha^{1,2}, Ewout W. Steyerberg^{3,4}

¹Center for Outcomes Research, JPS Health Network, Fort Worth, TX, USA
²Department of Biostatistics and Epidemiology, School of Public Health, UNT Health Science Center, Fort Worth, TX, USA
³Department of Public Health, Erasmus Medical Center, Rotterdam, Netherlands
⁴Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands

Corresponding author:
Rohit P. Ojha, DrPH
Center for Outcomes Research
JPS Health Network
1500 South Main Street
Fort Worth, TX 76104
Email: rojha@jpshealth.org
Fax: 1-817-702-6768

Word count: 758/800
Figures: 1

We read with interest a recent study that used real-world (i.e. observational) data from the German Hepatitis C-Registry.¹ The 12-week sustained virologic response (SVR) was compared between 8- and 12-week regimens of ledipasvir/sofosbuvir. The authors used classifications of intention to treat (ITT) and per protocol to define eligibility of patients for their analyses.¹ One classification of ITT defined eligibility as patients who completed treatment with either the 8- or 12-week ledipasvir/sofosbuvir regimen (SVR≈85%). The second classification of ITT defined eligibility as patients who initiated and completed either the 8- or 12-week ledipasvir/sofosbuvir regimen (SVR≈95%). Per protocol defined eligibility as patients who initiated and completed treatment, adhered to treatment throughout the duration, and had SVR status assessed 12 weeks post-treatment completion (SVR≈98%). Nevertheless, such use of the terms ITT and per protocol have undue popularity in real-world studies of direct-acting antivirals (DAAs).¹⁻⁴

ITT and per protocol are approaches to statistical analysis of randomized controlled trials (RCTs) and pertain to treatment status.⁵ Neither approach is used to define eligibility and neither approach is directly applicable to real-world studies. ITT involves analyzing outcomes for RCT participants based on the treatment to which they were randomized, regardless of adherence to the allocated treatment.⁵ ITT preserves the balance of known and unknown confounders between comparison groups (i.e. exchangeability), which is the key benefit of randomization for causal inference. In contrast, real-world studies have an inherent risk of confounding by indication, which no form of statistical adjustment can completely resolve.⁶ Per protocol involves analyzing outcomes for participants based on adherence with the allocated treatment, which addresses the issue of treatment misclassification.⁵ The potential reduction in treatment misclassification comes with the trade-off of breaking randomization; a per protocol analysis effectively converts the trial to a quasi-experimental study.⁵

1
2
3
4 The approach by Buggisch et al.¹ and others is incompatible with ITT or per protocol
5 definitions, and raises serious concerns about overestimated SVR in real-world studies. To
6 facilitate awareness of biasing mechanisms, *Figure 1* illustrates the four possible types of HCV-
7 infected patients who initiated DAAs in any real-world study regardless of treatment duration.
8
9 The distribution of these four patient types across regimens (e.g. 8- or 12-weeks) ultimately
10 determines the observed SVR incidence. Given that we cannot rely on randomization to
11 designate treatment status as in an RCT and the planned treatment duration (8 weeks or 12
12 weeks) was not recorded in the registry,¹ we must rely on exposure to treatment for eligibility.
13
14 Treatment duration could have been modified based on an intermediate measure of response,
15 which exacerbates the potential for confounding by indication. Nevertheless, we emphasize that
16 all four patient types would be eligible for the analysis. Type 1 and 2 patients were followed
17 through treatment completion and 12-week SVR assessment, and SVR was achieved by type 1
18 but not type 2 patients. Type 3 patients completed treatment, but the SVR status was unknown
19 because of loss to follow-up (e.g. some barrier to care), whereas type 4 patients were lost to
20 follow-up before completing treatment (e.g. side-effects or other reasons for discontinuation)
21 and SVR status was also unknown. Buggisch et al.¹ excluded type 4 patients because of
22 missing SVR status, but these patients were eligible albeit unlikely to achieve SVR. In addition,
23 the main analyses (labeled “per protocol”) excluded type 3 patients because of missing SVR
24 status despite SVR being possible but unknown. Such exclusion relies on the unrealistic
25 assumption that excluded cases were missing completely at random.⁷ Non-random exclusion of
26 patients based on outcome status leads to a selected population of patients who completed
27 treatment and had a high probability of SVR. Even the lowest estimate of SVR reported in the
28 study (85%) may be an overestimate.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 Given well-known problems with complete case analysis,⁷ the challenge is how to handle
57 patients with missing outcome data because of loss to follow-up. This challenge applies to
58 RCTs and real-world studies, and no consensus has been established about the best approach.
59
60
61
62
63
64
65


1
2
3
4 A simple approach is to designate worst-case and best-case scenarios, where none of the
5
6 individuals with missing SVR status would have achieved SVR or all of the individuals would
7
8 have achieved SVR, respectively.⁸ The range of estimates based on these designations can be
9
10 informative unless extensively missing SVR status is present.⁸ More sophisticated approaches
11
12 include multiple imputation and inverse probability weighting, but these approaches are not
13
14 necessarily superior in all scenarios.⁸⁻¹⁰
15
16

17 We conclude that the interpretation of favorable response with 8- or 12-week treatment
18
19 and the observed small differences between these regimens is problematic. Some limitations of
20
21 real-world data cannot be overcome. Sensitivity analyses and cautious interpretation are
22
23 encouraged.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C. *J Hepatol*. 2017.
2. Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. *Clin Infect Dis*. 2017;64(12):1711-1720.
3. Zeng QL, Xu GH, Zhang JY, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. *J Hepatol*. 2017;66(6):1123-1129.
4. Fox DS, McGinnis JJ, Tonnu-Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. *J Gastroenterol Hepatol*. 2017;32(6):1136-1142.
5. Shadish WR, Cook TD, Campbell DT. *Experimental and quasi-experimental designs for generalized causal inference*. Wadsworth Cengage learning; 2002.
6. Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *J Clin Epidemiol*. 2010;63(1):64-74.
7. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. *Am J Epidemiol*. 1995;142(12):1255-1264.
8. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ*. 2009;338:b2393.
9. Lewin A, Brondeel R, Benmarhnia T, Thomas F, Chaix B. Attrition Bias Related to Missing Outcome Data: A Longitudinal Simulation Study. *Epidemiology*. 2018;29(1):87-95.
10. Groenwold RH, Donders AR, Roes KC, Harrell FE, Jr., Moons KG. Dealing with missing outcome data in randomized trials and observational studies. *Am J Epidemiol*. 2012;175(3):210-217.

Figure 1. Distribution of patient types and follow-up in real-world studies of direct-acting antivirals for hepatitis C virus infections.^a



^aThe diamond at 12-week follow-up for patient type 1 represents sustained virologic response (SVR) and the circle for type 2 represents no SVR. Patient types without these symbols indicate loss to follow-up.

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: OJHA_COI_DISCLOSURE.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: STEYERBERG_COI_DISCLOSURE.pdf](#)